ADMA Biologics Inc (ADMA) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 14 from a previous price target of $24 . Maxim Group advised their investors in a research report released on Jul 25, 2016.
ADMA Biologics Inc closed down -0.0501 points or -0.78% at $6.34 with 99,749 shares getting traded on Wednesday. Post opening the session at $6.31, the shares hit an intraday low of $6.2801 and an intraday high of $6.5775 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 5, 2016, James Mond (CSO/CMO) purchased 770 shares at $6.50 per share price. According to the SEC, on May 5, 2016, Brian Lenz (CFO) purchased 2,500 shares at $6.50 per share price. On May 5, 2016, Adam S Grossman (CEO) purchased 200,000 shares at $6.50 per share price, according to the Form-4 filing with the securities and exchange commission.
ADMA Biologics Inc. is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The Company’s lead product candidate RI-002 is intended for the treatment of primary immune deficiency disease (PIDD). RI-002 is an injectable immune globulin derived from human plasma with levels of naturally occurring polyclonal antibodies as well as levels of antibodies targeted to respiratory syncytial virus (RSV). The company’s RI-002 demonstrated Phase III results and attained its primary endpoint and preliminary analysis indicates that the treatment with RI-002 resulted in no serious bacterial infections (SBI’s) observed in study subjects during the trial.